Key points are not available for this paper at this time.
This work was supported by National Institute on Aging Grants P01 AG03991 and P50 AG05681. Disclosure: Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Since July 2003, Dr. Morris participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Elan, Eli Lilly and Company, Merck, and Wyeth. In 2003 and 2004, Dr. Morris served as a consultant for or received speaking honoraria from the following companies: Amgen, Axonyx, BristolMyersSquibb, Codman-Johnson & Johnson, Eisai, Elan, Forest Labs, Neurochem, Novartis, Sanofi-Aventis, and Shionogi-Glaxo-Smith-Kline. Reprints: John C. Morris, MD, Friedman Distinguished Professor of Neurology Alzheimer's Disease Research Center, Washington University, 4488 Forest Park, Suite 130, St. Louis, MO 63108 (e-mail: email protected).
&NA; (Fri,) studied this question.